Medtronic has implanted the first patient with its CoreValve system in a clinical trial in Japan.

The trial will evaluate the safety and effectiveness of the Medtronic CoreValve system in patients with symptomatic, severe aortic stenosis who are at high risk or are ineligible for open-heart surgery.

The trial is being led by Professor Yoshiki Sawa at Osaka University Hospital.

The company also received Korea Food & Drug Administration approval for its CoreValve system last month.

Medtronic vice-president John Liddicoat said the successful results from the Japanese and Korean trials form the key steps for the transcatheter valve therapies to patients suffering from severe aortic stenosis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.